BillionToOne, Inc. - Class A common stock (BLLN)

Billiontoone (NASDAQ:BLLN) reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reit

Nancy Johnson liquidated 801 shares via a pre-established Rule 10b5-1 plan, retaining a $2.6 million stake in the molecular diagnostics firm.

Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five companies to consider owning for the next five-plus years.

This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.

BillionToOne (BLLN) Q1 2026 Earnings Transcript

This fintech firm delivers mobile-first, no-fee banking services to U.S. consumers underserved by traditional banks.

This diagnostics firm delivers precision molecular testing for prenatal and oncology use to hospitals and research centers.

Navan delivers an AI-powered platform for travel, payments, and expense management to enterprise clients in the business software sector.